Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Appoints Thomas Bailey as Chief Financial Officer
SEATTLE , Jan. 16, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Thomas Bailey has been appointed chief financial officer, effective January 16, 2018 .    Mr.
View HTML
Toggle Summary NanoString Technologies Provides Preliminary Operational and Financial Results for Fourth Quarter and Fiscal Year 2017
Fourth Quarter Product and Service Revenue Exceeds High End of Company Guidance
View HTML
Toggle Summary NanoString and RikenGenesis Announce Partnership to Commercialize nCounter-Based Diagnostic Assays in Japan
NanoString and Riken Genesis, a subsidiary of Sysmex, partner to register and commercialize NanoString's Lymphoma Subtyping Test for diagnostic use in Japan
View HTML
Toggle Summary NanoString Technologies Highlights Advances in Precision Oncology at the 59th Annual Meeting of the American Society of Hematology
More than 45 Abstracts Highlight the Value of the nCounter Platform in Hematology, including 11 that Demonstrate the Potential Clinical Utility of the Lymphoma Subtyping Test Company Announces Launch of Vantage 3D DNA:RNA:Protein Hematology Assays SEATTLE , Dec.
View HTML
Toggle Summary NanoString Highlights Record Number of nCounter-Based Research Abstracts at the 2017 Annual Meeting of the Society of Immunotherapy of Cancer (SITC)
45 Abstracts Demonstrate the Value of the nCounter Platform for Immuno-Oncology Research Studies Indicate the Clinical Relevance of the Tumor Inflammation Signature for Multiple Immunotherapies SEATTLE , Nov. 09, 2017 (GLOBE NEWSWIRE) --   NanoString Technologies, Inc.
View HTML
Toggle Summary NanoString Technologies Releases Operating Results for Third Quarter of 2017
SEATTLE , Nov. 02, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter of 2017. The results were consistent with the company's
View HTML
Toggle Summary NanoString and the NSABP Foundation Enter into Agreement to Study Immunophenotypes in Colorectal Cancer
Collaboration will use PanCancer IO360 Assay Which Incorporates the Tumor Inflammation Signature (TIS) and mismatch repair genes (MMR) for assessment of MSI-H phenotype
View HTML
Toggle Summary NanoString Announces Preliminary Revenue for Third Quarter of Fiscal Year 2017
SEATTLE , Oct. 11, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced preliminary total revenue of approximately $25.9 million to $26.9 million for the third quarter,
View HTML
Toggle Summary NanoString's Hyb & Seq™ Enables Liquid Biopsy by the Direct Capture and Sequencing of Cell-Free DNA
Simple Workflow Allows Target Capture and Sequencing Initiation in About One Hour
View HTML
Toggle Summary NanoString to Webcast Presentation at the 2017 Morgan Stanley Global Healthcare Conference
SEATTLE , Sept. 07, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies , Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it will webcast the company's presentation at the 2017 Morgan Stanley Global Healthcare
View HTML